|
1
|
Husby G: Amyloidosis and rheumatoid
arthritis. Clin Exp Rheumatol. 3:173–180. 1985.
|
|
2
|
Sahoo S, Reeves W and DeMay RM: Amyloid
tumor: a clinical and cytomorphologic study. Diagn Cytopathol.
28:325–328. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aono J, Yamagata K and Yoshida H: Local
amyloidosis in the hard palate: a case report. Oral Maxillofac
Surg. 13:119–122. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weiss SW and Goldblum JR: Enzinger and
Weiss’s Soft Tissue Tumors. 4th edition. Mosby Elsevier;
Philadelphia, PA, USA: 2001
|
|
5
|
Krishnan J, Chu WS, Elrod JP and Frizzera
G: Tumoral presentation of amyloidosis (amyloidomas) in soft
tissues. A report of 14 cases. Am J Clin Pathol. 100:135–144.
1993.PubMed/NCBI
|
|
6
|
Khan SM, Birch PJ, Bass PS, Williams JH
and Theaker JM: Localized amyloidosis of the lower genitourinary
tract: a clinicopathological and immunohistochemical study of nine
cases. Histopathology. 21:143–147. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ihling C, Weirich G, Gaa A and Schaefer H:
Amyloid tumors of the lung - an immunocytoma? Pathol Res Pract.
192:446–452. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deans GT, Hale RJ, McMahon RF and Brough
WA: Amyloid tumour of the colon. J Clin Pathol. 48:592–593. 1995.
View Article : Google Scholar
|
|
9
|
Sie MP, van der Wiel HE, Smedts FM and de
Boer AC: Human recombinant insulin and amyloidosis: an unexpected
association. Neth J Med. 68:138–140. 2010.PubMed/NCBI
|
|
10
|
Dische FE, Wernstedt C, Westermark GT,
Westermark P, Pepys MB, Rennie JA, Gilbey SG and Watkins PJ:
Insulin as an amyloid-fibril protein at sites of repeated insulin
injections in a diabetic patient. Diabetologia. 31:158–161. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Störkel S, Schneider HM, Müntefering H and
Kashiwagi S: Iatrogenic, insulin-dependent, local amyloidosis. Lab
Invest. 48:108–111. 1983.PubMed/NCBI
|
|
12
|
Swift B: Examination of insulin injection
sites: an unexpected finding of localized amyloidosis. Diabet Med.
19:881–882. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Muzaffar M and Ahmad A: The mechanism of
enhanced insulin amyloid fibril formation by NaCl is better
explained by a conformational change model. PloS One. 6:e279062011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yumlu S, Barany R, Eriksson M and Röcken
C: Localized insulin-derived amyloidosis in patients with diabetes
mellitus: a case report. Hum Pathol. 40:1655–1660. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Albert SG, Obadiah J, Parseghian SA,
Yadira Hurley M and Mooradian AD: Severe insulin resistance
associated with subcutaneous amyloid deposition. Diabetes Res Clin
Pract. 75:374–376. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shikama Y, Kitazawa J, Yagihashi N, Uehara
O, Murata Y, Yajima N, Wada R and Yagihashi S: Localized
amyloidosis at the site of repeated insulin injection in a diabetic
patient. Intern Med. 49:397–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
El-Agnaf OM, Jakes R, Curran MD, Middleton
D, Ingenito R, Bianchi E, Pessi A, Neill D and Wallace A:
Aggregates from mutant and wild-type α-synuclein proteins and NAC
peptide induce apoptotic cell death in human neuroblastoma cells by
formation of β-sheet and amyloid-like filaments. FEBS letters.
440:71–75. 1998.
|
|
18
|
Hertel C, Hauser N, Schubenel R,
Seilheimer B and Kemp JA: β-amyloid-induced cell toxicity:
enhancement of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide-dependent cell death. J Neurochem. 67:272–276. 1996.
|
|
19
|
Meratan AA, Ghasemi A and Nemat-Gorgani M:
Membrane integrity and amyloid cytotoxicity: a model study
involving mitochondria and lysozyme fibrillation products. J Mol
Biol. 409:826–838. 2011. View Article : Google Scholar
|
|
20
|
Maurice T, Lockhart BP and Privat A:
Amnesia induced in mice by centrally administered β-amyloid
peptides involves cholinergic dysfunction. Brain Res. 706:181–193.
1996.
|
|
21
|
Morimoto K, Yoshimi K, Tonohiro T, Yamada
N, Oda T and Kaneko I: Co-injection of β-amyloid with ibotenic acid
induces synergistic loss of rat hippocampal neurons. Neuroscience.
84:479–487. 1998.
|
|
22
|
Piermartiri TC, Vandresen-Filho S, de
Araújo Herculano B, Martins WC, Dal’agnolo D, Stroeh E, Carqueja
CL, Boeck CR and Tasca CI: Atorvastatin prevents hippocampal cell
death due to quinolinic acid-induced seizures in mice by increasing
Akt phosphorylation and glutamate uptake. Neurotox Res. 16:106–115.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prediger RD, Franco JL, Pandolfo P,
Medeiros R, Duarte FS, Di Giunta G, Figueiredo CP, Farina M,
Calixto JB, Takahashi RN and Dafre AL: Differential susceptibility
following β-amyloid peptide-(1–40) administration in C57BL/6 and
Swiss albino mice: Evidence for a dissociation between cognitive
deficits and the glutathione system response. Behav Brain Res.
177:205–213. 2007.
|
|
24
|
Klunk WE, Pettegrew J and Abraham DJ:
Quantitative evaluation of congo red binding to amyloid-like
proteins with a β-pleated sheet conformation. J Histochem Cytochem.
37:1273–1281. 1989.PubMed/NCBI
|
|
25
|
Wallymahmed ME, Littler P, Clegg C,
Haqqani MT and Macfarlane IA: Nodules of fibrocollagenous scar
tissue induced by subcutaneous insulin injections: a cause of poor
diabetic control. Postgrad Med J. 80:732–733. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Westermark P, Araki S, Benson MD, Cohen
AS, Frangione B, Masters CL, Saraiva MJ, Sipe JD, Husby G, Kyle RA
and Selkoe D: Nomenclature of amyloid fibril proteins: Report from
the meeting of the International Nomenclature Committee on
Amyloidosis; August 8–9, 1998; Part 1: Amyloid. 6. pp. 63–66.
1999
|
|
27
|
Westermark P, Benson MD, Buxbaum JN, Cohen
AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ and
Sipe JD: Amyloid fibril protein nomenclature - 2002. Amyloid.
9:197–200. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cortés A: Primary cutaneous amyloidosis.
Dermatologica. 139:109–114. 1969.
|
|
29
|
Kumar V, Abbas AK, Fausto N and Aster JC:
Robbins and Cotran Pathologic Basis of Disease. 8th edition.
Saunders Elsevier; Philadelphia, PA, USA: 2010
|
|
30
|
Rooban T, Saraswathi T, Al Zainab FH, Devi
U, Eligabeth J and Ranganathan K: A light microscopic study of
fibrosis involving muscle in oral submucous fibrosis. Indian J Dent
Res. 16:131–134. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lasagna-Reeves CA, Clos AL, Midoro-Hiriuti
T, Goldblum RM, Jackson GR and Kayed R: Inhaled insulin forms toxic
pulmonary amyloid aggregates. Endocrinology. 151:4717–4724. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hazenberg BP, van Gameren II, Bijzet J,
Jager PL and van Rijswijk MH: Diagnostic and therapeutic approach
of systemic amyloidosis. Neth J Med. 62:121–128. 2004.PubMed/NCBI
|
|
33
|
Yamamoto T: Amyloidosis in the skin.
Amyloidosis - an Insight to Disease of Systems and Novel Therapies.
Güvenç IA: InTech; Rijecka, Croatia: pp. 91–104. 2011
|
|
34
|
Touart DM and Sau P: Cutaneous deposition
diseases. Part I. J Am Acad Dermatol. 39:149–171. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moon AO, Calamia KT and Walsh JS: Nodular
amyloidosis: review and long-term follow-up of 16 cases. Arch
Dermatol. 139:1157–1159. 2003.PubMed/NCBI
|
|
36
|
Truhan AP, Garden JM and Roenigk HH Jr:
Nodular primary localized cutaneous amyloidosis:
immunohistochemical evaluation and treatment with the carbon
dioxide laser. J Am Acad Dermatol. 14:1058–1062. 1986. View Article : Google Scholar
|
|
37
|
Steciuk A, Dompmartin A, Troussard X,
Verneuil L, Macro M, Comoz F and Leroy D: Cutaneous amyloidosis and
possible association with systemic amyloidosis. Int J Dermatol.
41:127–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Woollons A and Black MM: Nodular localized
primary cutaneous amyloidosis: a long-term follow-up study. Br J
Dermatol. 145:105–109. 2001. View Article : Google Scholar : PubMed/NCBI
|
